Usher Syndrome - Pipeline Review, H1 2017

  • ID: 4318759
  • Report
  • 34 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Editas Medicine Inc
  • ProQR Therapeutics NV
  • Sanofi
  • MORE
Usher Syndrome - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Usher Syndrome - Pipeline Review, H1 2017, provides an overview of the Usher Syndrome (Genetic Disorders) pipeline landscape.

Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration, prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids and Vitamin A supplementation.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Usher Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Usher Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Usher Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Usher Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Discovery stages are 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Usher Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Usher Syndrome (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Usher Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Usher Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Usher Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Usher Syndrome (Genetic Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Usher Syndrome (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Usher Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Editas Medicine Inc
  • ProQR Therapeutics NV
  • Sanofi
  • MORE
  1. Introduction
  2. Usher Syndrome - Overview
  3. Usher Syndrome - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Usher Syndrome - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Usher Syndrome - Companies Involved in Therapeutics Development
  15. Amgen Inc
  16. Editas Medicine Inc
  17. ProQR Therapeutics NV
  18. Sanofi
  19. Usher Syndrome - Drug Profiles
  20. Gene Therapy for Usher Syndrome - Drug Profile
  21. Product Description
  22. Mechanism Of Action
  23. R&D Progress
  24. Gene Therapy to Activate MYO7A for Usher Syndrome - Drug Profile
  25. Product Description
  26. Mechanism Of Action
  27. R&D Progress
  28. NT-501 - Drug Profile
  29. Product Description
  30. Mechanism Of Action
  31. R&D Progress
  32. QRX-411 - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. QRX-421 - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. SAR-421869 - Drug Profile
  41. Product Description
  42. Mechanism Of Action
  43. R&D Progress
  44. Usher Syndrome - Dormant Projects
  45. Usher Syndrome - Product Development Milestones
  46. Featured News & Press Releases
  47. May 01, 2017: ProQR to Present Data on QRX-411 at ARVO
  48. May 01, 2017: ProQR to Present Data on QRX-421 at ARVO
  49. Sep 18, 2012: Neurotech Pharmaceuticals Provides Update On NT-501
  50. Appendix
  51. Methodology
  52. Coverage
  53. Secondary Research
  54. Primary Research
  55. Expert Panel Validation
  56. Contact Us
  57. Disclaimer
List of Tables
  1. Number of Products under Development for Usher Syndrome, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Products under Development by Companies, H1
  5. Products under Development by Universities/Institutes, H1
  6. Number of Products by Stage and Target, H1
  7. Number of Products by Stage and Mechanism of Action, H1
  8. Number of Products by Stage and Route of Administration, H1
  9. Number of Products by Stage and Molecule Type, H1
  10. Usher Syndrome - Pipeline by Amgen Inc, H1
  11. Usher Syndrome - Pipeline by Editas Medicine Inc, H1
  12. Usher Syndrome - Pipeline by ProQR Therapeutics NV, H1
  13. Usher Syndrome - Pipeline by Sanofi, H1
  14. Usher Syndrome - Dormant Projects, H1
List of Figures
  1. Number of Products under Development for Usher Syndrome, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Targets, H1
  4. Number of Products by Stage and Targets, H1
  5. Number of Products by Mechanism of Actions, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Routes of Administration, H1
  8. Number of Products by Stage and Routes of Administration, H1
  9. Number of Products by Molecule Types, H1
  10. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • Editas Medicine Inc
  • ProQR Therapeutics NV
  • Sanofi
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll